Process characterization for upstream and downstream process development

Animal Cell Biotechnology: In Biologics Production

Volumn , Issue , 2014, Pages 598-647

  Janakiraman, Vijay ^a   Westoby, Matthew ^a   Conley, Lynn ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETIC ENGINEERING;

DOWNSTREAM PROCESS DEVELOPMENT; PROCESS CHARACTERIZATION;

BIOTECHNOLOGY;

EID: 84944964023     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1515/9783110278965.598     Document Type: Chapter

References (53)

1. Eon-duval A, Valax P, Solacroup T, et al. Application of the quality by design approach to the drug substance manufacturing process of an Fc fusion protein: towards a global multi-step design space. J Pharm Sci 2012;101:3604-3618.
2. th May 2014.
3. Korakianiti E, Rekkas D. Statistical thinking and knowledge management for quality-driven design and manufacturing in pharmaceuticals. Pharm Res 2011;28:1465-1479.
4. Yacoub F, Lautens J, Lucisano L, Banh W. Application of Quality by Desig Principles to Legacy Drug Products. J Pharm Innov 2011;6:61-68.
5. th May 2014.
6. th May 2014.
7. th May 2014.
8. th May 2014.
9. Kozlowski S, Swann P. Considerations for Biotechnology Product Quality by Design. In: Rathore AS, Mhatre R (eds). Quality by Design for Biopharmaceuticals: Principles and Case Studies. 1st ed. New York, NY! USA: John Wiley and Sons; 2009:9-30.
10. Kozlowski S, Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv Drug Delivery Rev 2006;58:707-722.
11. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol 2009;27:26-34.
12. Rathore AS. Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 2009;27:546-553.
13. Arora T, Greene R, Mercer J, et al. Quality by Design for Biotechnology Products - Part 1: A PhRMA Working Group's Advice on Applying QbD to Biotech. Biopharm Int 2009;22:26-36.
14. Looby M, Ibarra N, Pierce JJ, et al. Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein. Biotechnol Prog 2011;27:1718-1729.
15. Martin-Moe S, Lim FJ, Wong RL, et al. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design. J Pharm Sci 2011;100:3031-3043.
16. th May 2014.
17. Cook S, Patton KA, Bazemore LR. Quality by design in the CMO environment. Biopharm Int 2007;20:28-37.
18. Chhatre S, Farid SS, Coffman J, et al. How implementation of Quality by Design and advances in Biochemical Engineering are enabling efficient bioprocess development and manufacture. J Chem Technol Biot 2011;86:1125-1129.
19. Cecchini DJ. Applications of Design Space for Biopharmaceutical Purification Processes. In: Rathore AS, Mhatre R (eds). Quality by Design for Biopharmaceuticals: Principles and Case Studies. 1st ed. New York, NY! USA: John Wiley and Sons; 2009:127-142.
20. Shivhare M, McCreath G. Practical Considerations for DoE Implementation in Quality By Design. BioProcess Int 2010;8:22-30.
21. PDA technical report no. 42: Process validation of protein manufacturing. Parenteral drug Association. PDA Journal Pharm Sci Technol 2005;59:1-28.
22. Mire-Sluis A, Ramnarine E, Siemiatkoski J, et al. Practical Applications of Quality Risk Management. Bioproc Int 2010;8:20-32.
23. th July 2009, Bethesda, MD, USA.
24. Charoo NA, Ali AA. Quality risk management in pharmaceutical development. Drug Dev Ind Pharm 2013;39:947-960.
25. Stark C. Practical considerations to risk assessments for efficient use in pharmaceutical development and production. SBE's 3rd International Conference on Accelerating Biopharmaceutical Development and Quality by Design in Biologics 2013; Coronado Island, CA.
26. Seely RJ, Haury J. Applications of Failure Modes and Effects Analysis to Biotechnology Manufacturing Processes. In: Rathore AS, Sofer G (eds) Process Validation in Manufacturing of Biopharmaceuticals. 3rd ed. Boca Raton, FL, USA: CRC Press, Taylor and Francis; 2012:51-62.
27. Schenerman M, Axley MJ, Oliver CN, et al. Using a Risk Assessment Process to Determine Criticality of Product Quality Attributes. In: Rathore AS, Mhatre R (eds). Quality by Design for Biopharmaceuticals: Principles and Case Studies. 1st ed. New York, NY USA: John Wiley and Sons; 2009:53-84.
28. vanHoek P, Harms J, Wang X, Rathore AS. Case Study on Definition of Process Design Space for a Microbial Fermentation Step. In: Rathore AS, Mhatre R (eds). Quality by Design for Biopharmaceuticals: Principles and Case Studies. 1st ed. New York, NY USA: John Wiley and Sons; 2009:85-110.
29. van der Voet H, Perry JN, Amzal B, Paoletti C. A statistical assessment of differences and equivalences between genetically modified and reference plant varieties. BMC Biotechnol 2011;11:15.
30. Pieracci J, Yusuf-Makagiansar H. Leveraging Multivariate Analysis Tools to Qualify Scaled-Down Models. In: Rathore AS, Sofer G (eds). Process Validation in Manufacturing of Biopharmaceuticals. 3rd ed. Boca Raton, FL, USA: CRC Press, Taylor and Francis; 2012:411-440.
31. Heath C, Kiss R. Cell culture process development: advances in process engineering. Biotechnol Prog 2007;23:46-51.
32. Nienow AW. Reactor engineering in large scale animal cell culture. Cytotechnology 2006;50:9-33.
33. Tsang VL, Wang AX, Yusuf-Makagiansar H, Ryll T. Development of a scale down cell culture model using multivariate analysis as a qualification tool. Biotechnol Prog 2014;30(1):152-160.
34. Betts JI, Doig SD, Baganz F. Characterization and application of a miniature 10 mL stirred-tank bioreactor, showing scale-down equivalence with a conventional 7 L reactor. Biotechnol Prog 2006;22:681-688.
35. Li F, Hashimura Y Pendleton R, Harms J, Collins E, Lee B. A systematic approach for scale-down model development and characterization of commercial cell culture processes. Biotechnol Prog 2006;22:696-703.
36. Ambler CM. The theory of scaling up laboratory data for the sedimentation type centrifuge. J Biochem Microbiol Technol Eng 1959;1:185-205.
37. Westoby M, Rogers JK, Haverstock R, et al. Modeling industrial centrifugation of mammalian cell culture using a capillary based scale-down system. Biotechnol Bioeng 2011;108:989-998.
38. Boychyn M, Yim SS, Bulmer M, et al. Performance prediction of industrial centrifuges using scale-down models. Bioproc Biosys Eng 2004;26:385-391.
39. Conley L, McPherson J, Thommes J. Validation of the Zevalin(R) Purification Process: A Case Study. In: Rathore AS, Sofer G (eds). Process Validation in Manufacturing of Biopharmaceuticals. 3rd ed. Boca Raton, FL, USA: CRC Press, Taylor and Francis; 2012:455-490.
40. Godavarti R, Petrone J, Robinson J, et al. Scaled-Down Models for Purification Processes: Approaches and Applications. In: Rathore AS, Sofer G (eds). Process Validation in Manufacturing of Biopharmaceuticals. 3rd ed. Boca Raton, FL, USA: CRC Press, Taylor and Francis; 2012:89-140.
41. th ed. Mississauga, ON, Canada: John Wiley and Sons; 2012.
42. Seely RJ, Seely JE. A Rational, Step-Wise Approach to Process Characterization. Biopharm Int 2003;16:24-34.
43. Frigon NL, Mathews D. Practical Guide to Experimental Design. 1st ed. New York, NY USA: John Wiley and Sons; 1996.
44. Mandenius CF, Brundin A. Bioprocess optimization using design-of-experiments methodology. Biotechnol Prog 2008;24:1191-1203.
45. Lenth RV. Response-Surface Methods in R, Using rsm. J Stat Softw 2009;32:1-17.
46. Abu-Absi SF, Yang L, Thompson P, et al. Defining process design space for monoclonal antibody cell culture. Biotechnol Bioeng 2010;106:894-905.
47. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005;21:11-16.
48. Follman DK, Fahrner RL. Factorial screening of antibody purification processes using three chromatography steps without protein A. J Chromatogr A 2004;1024:79-85.
49. Kelley BD. Establishing Process Robustness Using Designed Experiments. In: Sofer G, Zabriskie DW (eds). Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies. 1st ed. New York, NY USA: Marcel Dekker; 2000:29-60.
50. Xu Z, Li J, Zhou JX. Process development for robust removal of aggregates using cation exchange chromatography in monoclonal antibody purification with implementation of quality by design. Prep Biochem Biotechnol 2012;42:183-202.
51. Jiang C, Flansburg L, Ghose S, et al. Defining process design space for a hydrophobic interaction chromatography (HIC) purification step: application of quality by design (QbD) principles. Biotechnol Bioeng 2010;107:985-997.
52. Gardner AR, Smith TM. Identification and Establishment of Operating Ranges of Critical Process Variables. In: Sofer G, Zabriskie DW (eds). Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies. 1st ed. New York, NY USA: Marcel Dekker; 2000:61-76.
53. Pieracci J, Perry L, Conley L. Using partition designs to enhance purification process understanding. Biotechnol Bioeng 2010;107:814-824.